Mumbai, March 7 -- The agency has reaffirmed its 'Crisil A1+' rating on the short-term bank facilities of Epigral.

Crisil Ratings stated that the rating action reflects sustenance of the strong business risk profile of Epigral, supported by its continued focus on speciality and derivative business (54% share in revenue in the first nine months of fiscal 2025, compared with 42% in the corresponding period of previous fiscal and 30% in fiscal 2023), that is expected to improve further and contribute to around two-third of the revenue over the next two to three fiscals.

The revenue grew 37% on-year to Rs 1,923 crore in the first nine months of fiscal 2025, driven by volume growth of 15%, majorly from the derivatives and speciality business...